ALK and non-small cell lung carcinoma: In a pooled analysis, of clinical trials in which patients received ALK-TKIs for advanced NSCLC, the incidence of QTc interval prolongation with ceritinib, crizotinib, alectinib, and lorlatinib was 6.7%, 2.4%, 3.2%, and 0%.82